A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.
V. Moreno Garcia
Employment or Leadership Position - Institute of Cancer Research
R. D. Baird
Employment or Leadership Position - Institute of Cancer Research
Honoraria - Genentech
K. J. Shah
Employment or Leadership Position - Institute of Cancer Research
B. Basu
Employment or Leadership Position - Institute of Cancer Research
N. Tunariu
Employment or Leadership Position - Institute of Cancer Research
M. Blanco
Employment or Leadership Position - Institute of Cancer Research
P. A. Cassier
Employment or Leadership Position - Institute of Cancer Research
J. V. Pedersen
Employment or Leadership Position - Institute of Cancer Research
M. Puglisi
Employment or Leadership Position - Institute of Cancer Research
D. Sarker
Employment or Leadership Position - Institute of Cancer Research
D. Papadatos-Pastos
Employment or Leadership Position - Institute of Cancer Research
A. G. Omlin
Employment or Leadership Position - Institute of Cancer Research
A. Biondo
Employment or Leadership Position - Institute of Cancer Research
J. A. Ware
Employment or Leadership Position - Genentech
Stock Ownership - Roche
H. Koeppen
Employment or Leadership Position - Genentech
Stock Ownership - Roche
G. G. Levy
Employment or Leadership Position - Genentech
Stock Ownership - Roche
K. E. Mazina
Employment or Leadership Position - Genentech
Stock Ownership - Roche
J. S. De Bono
Employment or Leadership Position - Institute of Cancer Research
Consultant or Advisory Role - Arno Therapeutics; AstraZeneca; Exelixis; Genentech; GlaxoSmithKline; Merck; Novartis; Pfizer
Honoraria - Arno Therapeutics; AstraZeneca; Exelixis; Genentech; GlaxoSmithKline; Merck; Novartis; Pfizer
Research Funding - Phase I Trials of GDC0941